Fluidigm develops microfluidics technologies and platforms, and the company secured NIH funding to support COVID-19 testing efforts. The article notes that in about 17 months the company "has gone from working with sharks to Vikings." Fluidigm is based in South San Francisco. Recently the company received a $250 million infusion of capital. That financing was reported as co-led by investor Eli Casdin. Other operational details, revenue, user metrics, and instrument types for the financing were not disclosed in the provided text.

Total raised

$250M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2022